National emergency department (ED) visit prevalence and costs for selected diseases that can be transmitted by water were estimated using large healthcare databases (acute otitis externa, campylobacteriosis, cryptosporidiosis, Escherichia coli infection, free-living ameba infection, giardiasis, hepatitis A virus (HAV) infection, Legionnaires' disease, nontuberculous mycobacterial (NTM) infection, Pseudomonas-related pneumonia or septicemia, salmonellosis, shigellosis, and vibriosis or cholera). An estimated 477,000 annual ED visits (95% CI: 459,000-494,000) were documented, with 21% (n ¼ 101,000, 95% CI: 97,000-105,000) resulting in immediate hospital admission. The remaining 376,000 annual treat-and-release ED visits (95% CI: 361,000-390,000) resulted in $194 million in annual direct costs. Most treat-and-release ED visits (97%) and costs ($178 million/year) were associated with acute otitis externa. HAV ($5.5 million), NTM ($2.3 million), and salmonellosis ($2.2 million) were associated with next highest total costs. Cryptosporidiosis ($2,035), campylobacteriosis ($1,783), and NTM ($1,709) had the highest mean costs per treat-and-release ED visit. Overall, the annual hospitalization and treat-and-release ED visit costs associated with the selected diseases totaled $3.8 billion. As most of these diseases are not solely transmitted by water, an attribution process is needed as a next step to determine the proportion of these visits and costs attributable to waterborne transmission.
INTRODUCTION
Emergency departments (EDs) are unique outpatient care settings whose vital role includes coordinating pre-hospital emergency medicine, administering rapid diagnostics and treatments, as well as providing unrestricted access to care and a round-the-clock gateway to inpatient care (Tang et al. ; Schuur & Venkatesh ) . In the United States, nearly 100 million annual outpatient acute care visits occur in EDs, with two-thirds occurring on weekends or after physician office hours (Pitts et al. ) . The number of ED visits in the United States increased from 1997 to 2001 at twice the rate that would be expected from population growth alone, largely driven by adult Medicaid patients (Tang et al. ) .
Additionally, the proportion of inpatients admitted from EDs increased nationally from 1993 to 2006, highlighting the growing role of these facilities as a gateway to inpatient care (Schuur & Venkatesh ) . Treat-and-release ED visits also comprise an estimated 40% of acute care encounters occurring within 30 days of hospital discharge (Vashi et al. Previously, Collier et al. () found nearly 82,000 hospitalizations occur annually at a cost of $1.3 billion each
year for eight diseases that can be associated with water exposuresacute otitis externa (swimmer's ear), campylobacteriosis, cryptosporidiosis, giardiasis, Legionnaires' disease, nontuberculous mycobacterial (NTM) infection, salmonellosis, and shigellosis. An analysis examining deaths associated with these diseases and an additional five that can be transmitted by water (Escherichia coli (E. coli) infection, free-living ameba infection, hepatitis A virus (HAV) infection, Pseudomonas infection, and vibriosis/cholera) documented the occurrence of 6,939 deaths each year, with 91% associated with Legionnaires' disease, NTM infection, and Pseudomonas-related pneumonia or septicemia (Gargano et al. ) . To better describe outpatient ED care for diseases that can be transmitted by water in the United States, national ED visit prevalence, direct costs, visit characteristics, and payer-breakdowns were quantified.
To tabulate total ED visit and hospitalization costs for the selected diseases, the number of national hospitalizations and associated direct costs for the diseases not previously published were calculated and then totaled with the published hospitalization estimates and ED visit analyses described here.
METHODS
US waterborne disease and outbreak surveillance data and existing literature were used to identify 13 diseases that can be transmitted by water (Craun et National annual numbers of ED visits for each disease were estimated using HCUP NEDS data from 2008 to 2012. Records that indicated that the patient was treated and released from the ED or admitted were used for analyses. Visits with all-listed diagnoses that included the diseases defined above were analyzed. SAS survey procedures were used to apply sampling weights to account for the complex sampling design and to yield annual national estimates of ED visits and measures of uncertainty for the selected diseases (SAS Institute Inc., USA). The weighted proportions of the total visits attributed to private insurance, Medicare, Medicaid, and other types of payment, including self-pay and military Tricare plans, were also calculated for each disease.
Next, direct costs for treat-and-release ED visits for each disease were calculated by insurance type using the Market- claim not incorporated into inpatient admission because room and board charge not found) (Truven Health Analytics b), ED visits associated with an inpatient admission on the same day were excluded. To provide a full accounting of costs including costs for prescription drugs, only visits by individuals with pharmaceutical insurance coverage were examined. Outpatient pharmaceutical claims were added to the visit costs when prescriptions were filled on the same day as the visit. The mean insurer costs, patient out-of-pocket costs, and total costs per ED visit were calculated in 2014 US dollars by disease and insurance source, using healthcare commodity price conversion rates (Bureau of Labor Services ). To account for outliers that could skew mean cost calculations, ED visits were excluded if they resulted in zero total cost or the log of the total cost for that ED visit was at least three standard deviations from the log mean total cost (Bhattarai ) . Cost estimates based on very small sample sizesthat is, less than five insurance source, using healthcare commodity price conversion rates (Bureau of Labor Services ). If patients had more than one associated hospital stay within a 365-day period, costs were aggregated to represent one hospitalization episode. Hospitalization costs also included costs for prescription medications and ED visits related to the hospitalization stay (i.e. ED visits that were not 'treat-andrelease'). Cost estimates based on less than five patients per disease and insurance source were not reported. The overall mean cost per hospitalization episode was multiplied by the annual number of hospitalizations to calculate a total annual direct hospitalization cost for each disease. Finally, total costs of hospitalization episodes for the 13 selected diseases were added to the total annual costs of treat-and-release ED visits to summarize overall annual costs.
RESULTS
An estimated 476,543 annual total ED visits (95% CI: 459,295-493,791) were documented for the 13 selected diseases ( Table 1) . Most of these (n ¼ 375,021 (79%)) resulted from acute otitis externa. After acute otitis externa, the next most common diagnosis groups were Pseudomonas-related pneumonia or septicemia (n ¼ 54,211 (11%)), NTM infection (n ¼ 14,122 (3%)), and salmonellosis (n ¼ 9,574 (2%)). Most Pseudomonas visits were associated with pneumonia (n ¼ 39,864 (74%)), followed by septicemia (n ¼ 16,357 (30%)). Visits for NTM infections were most often 
Giardiasis The next highest numbers of ED visits overall were seen in illnesses from Pseudomonas and NTM infections; these pathogens are found in the environment and can grow and multiply in biofilms within water distribution system pipes 
CONCLUSIONS
The diseases studied here contribute to 500,000 US treatand-release ED visits and hospitalizations annually at a cost of nearly $4 billion each year. EDs play an important role in managing illnesses in the United States, but national costs and characteristics of ED visits associated with diseases that can be transmitted by water have not been previously well described. These findings highlight the importance of tabulating national healthcare outcomes and costs as an initial step towards better understanding the epidemiology of these diseases in the United States.
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